OncLive SOSS

Key Data Updates and Treatment Trends in Ovarian Cancer From ASCO 2025 - Episode 2

Data for First-Line Dostarlimab and Niraparib in Advanced Ovarian Cancer: The FIRST Trial

June 26, 2025

Tara Berman, MD, MS, Gottfried E. Konecny, MD

Tara Berman, MD, MS, and Gottfried E. Konecny, MD, discuss data for dostarlimab plus niraparib in advanced ovarian cancer.

EP. 1: Antibody-Drug Conjugates Could Continue to Reshape Ovarian Cancer Management

EP. 2: Data for First-Line Dostarlimab and Niraparib in Advanced Ovarian Cancer: The FIRST Trial

EP. 3: TRUST Trial: Outcomes With Radical Up-Front Surgery in Advanced Ovarian Cancer

EP. 4: Relacorilant Plus Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer: The ROSELLA Trial

EP. 5: Findings for Neoadjuvant IMNN-001 Plus Chemo in Newly Diagnosed, Advanced Epithelial Ovarian Cancer

EP. 6: Ongoing Research to Watch in Ovarian Cancer in 2025 and Beyond